Navigation Links
Stronger Backing for Drug-Coated Stents

New research proves drug-coated stents effectively combat death, heart attack and repeat procedures in the real world.//

A new study from researchers in the Netherlands indicates that patients in clinical trials of drug-coated stents represented a very select group of the total population. This new study takes a closer look at the effects of drug-coated stents on real-world patients, patients the researchers say tend to be older and sicker than those selected for clinical trials.

The study included more than 500 patients with previously untreated blocked arteries who were treated with drug-eluting stents. An additional 450 patients with comparable blockages were treated with bare metal stents. Sixty-eight percent of the patients in this trial did not meet the selection criteria of previous clinical trials.

Results of the one-year study show 9.7 percent of patients who received drug-eluting stents had a major adverse cardiac event, compared with 14.8 percent of patients treated with bare metal stents. Only 3.7 percent of patients with drug-eluting stents experienced renarrowing of the treated vessel, a common complication that leads to corrective procedures. However, 10.9 percent of patients with bare metal stents required repeat procedures to correct renarrowing of the artery.

Lead investigator Patrick W. Serruys, M.D., Ph.D., from Erasmus Medical Center in the Netherlands, says, “The treatment effects -- particularly the reduction of re-interventions -- were similar across very different subgroups of patients.” He says drug-eluting stents are the next major step in interventional cardiology.

In an accompanying editorial, David P. Fason, M.D., from the University of Chicago, says the research results “go a long way in re-assuring the practitioner that drug-eluting stents are in fact safe and effective in a wide variety of patients undergoing ‘real world’ angioplasty.” He concludes that the next step shoul d be a mandatory registry established by the Food and Drug Administration to report problems.


'"/>




Related medicine news :

1. Health Care Ties To Get Stronger Between India And Britain
2. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
3. Stronger Doses Fewer Administration for Breast Cancer
4. Stronger Quadricep Controls Knee Osteoarthritis
5. Old Indian Advice Has A Scientific Backing Now!
6. Fury over Backing of Health Shake-up
7. Failure of Drug-Coated Stent
8. Drug-Coated Stent
9. Drug-Coated Stents – Proven to be More Effectiv
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Drug-Coated Stents – Proven to be More Effectiv
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: